Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with
metastatic disease at diagnosis, many patients can be cured. Patients who fall into the poor
risk category or others who relapse can be successfully salvaged with high dose chemotherapy
and autologous stem cell transplant (AuSCT). As in other diseases such as myeloma, sequential
high dose chemotherapy and AuSCT may improve overall and disease free survival.
PURPOSE: Because prior investigations in GCT suggest that a subset of high risk or relapsed
patients may be cured with sequential cycles of high dose chemotherapy and AuSCT, we propose
investigating how well non-cross resistant conditioning regimens work in treating patients
with relapsed or high risk GCT.